AL-8326 is under clinical development by Advenchen Laboratories and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AL-8326’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Go deeper with GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AL-8326 overview
AL-8326 is under development for the treatment of advanced solid tumors including glioblastoma multiforme (GBM), small cell lung cancer, renal cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, endometrial cancer, cervical cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, ovarian cancer, breast cancer, colon cancer, head and neck cancer, prostate cancer, kidney cancer, bladder cancer, gastrointestinal stromal tumor and cholangiocarcinoma. It is administered through oral route. The drug candidate is a multikinase inhibitor that acts by targeting Aurora B, FGFR (fibroblast growth factor receptor) and VEGFR (vascular endothelial growth factor receptor).
Advenchen Laboratories overview
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAdvenchen Laboratories is a pharmaceutical company that offers healthcare solutions. The company conducts pharmaceutical research and develops small molecule cancer drug discovery programs. It provides pipeline such as angiogenesis inhibitors and small molecule protein tyrosine kinases inhibitors, among others. Advenchen Laboratories provides services such as producing inhibitors for the treatment of human colon cancer, liver cancer, gastric cancer, lungs and breast cancer, among others. Advenchen Laboratories also provides customized chemical intermediate services. The company operates in China and the US. Advenchen Laboratories is headquartered in Moorpark, California, the US.
For a complete picture of AL-8326’s drug-specific PTSR and LoA scores, buy the report here.
